Glaukos (GKOS) Scheduled to Post Earnings on Monday

Glaukos (NYSE:GKOS - Get Free Report) is set to announce its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Glaukos has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting analysts' consensus estimates of ($0.52). The company had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm's revenue was up 19.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.55) EPS. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Trading Up 2.7 %

Glaukos stock traded up $3.49 during trading hours on Monday, reaching $134.08. The stock had a trading volume of 471,028 shares, compared to its average volume of 569,984. The stock has a market cap of $6.75 billion, a PE ratio of -46.56 and a beta of 1.02. The company has a fifty day simple moving average of $129.22 and a 200-day simple moving average of $118.66. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. Glaukos has a 52 week low of $59.22 and a 52 week high of $136.60.

Insider Activity at Glaukos

In other news, COO Joseph E. Gilliam sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at $13,216,581.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the company's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $13,216,581.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Marc Stapley sold 6,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total transaction of $787,062.50. Following the transaction, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,250 shares of company stock worth $4,825,873. 6.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have commented on GKOS. Citigroup lowered Glaukos from a "buy" rating to a "neutral" rating and upped their price target for the company from $130.00 to $132.00 in a research report on Wednesday, July 10th. BTIG Research upped their target price on Glaukos from $131.00 to $139.00 and gave the company a "buy" rating in a report on Wednesday, August 28th. Stifel Nicolaus lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Truist Financial upped their price objective on shares of Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Finally, Piper Sandler set a $140.00 target price on shares of Glaukos in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $130.45.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.